An exploratory analysis of the ACCORD12/PRODIGE 2 phase III trial was carried out to retrospectively compare the benefit of neoadjuvant chemotherapy between the elderly ( 70 years ; n = 142 ) and younger patients ( < 70 years ; n = 442 ) , this analysis was not preplanned in the study protocol .